Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2019

Open Access 01-12-2019 | Bisoprolol | Research article

Bisoprolol transdermal patch for perioperative care of non-cardiac surgery in patients with hypertrophic obstructive cardiomyopathy

Authors: Yoichi Imori, Hitoshi Takano, Hiroshi Mase, Junya Matsuda, Hideto Sangen, Yuki Izumi, Yukichi Tokita, Takeshi Yamamoto, Wataru Shimizu

Published in: BMC Cardiovascular Disorders | Issue 1/2019

Login to get access

Abstract

Background

Non-cardiac surgery for hypertrophic obstructive cardiomyopathy (HOCM) is considered to require meticulous perioperative care. β-blockers are considered the first-line drugs for patients with HOCM, and they play a key role in preventing cardiovascular complications in perioperative care. The bisoprolol transdermal patch has recently become available in Japan, and it is useful for patients who are unable to take oral medication during perioperative care. The aim of this case series was to assess the hemodynamic features of patients with HOCM who used the bisoprolol transdermal patch during perioperative care for non-cardiac surgery.

Methods

Between August 2016 and August 2018, we retrospectively analyzed 10 consecutive cases of HOCM with the patients using the bisoprolol transdermal patch during perioperative care. Hemodynamic and echocardiographic features were evaluated before and after patients were switched from oral bisoprolol to transdermal patch therapy or started transdermal patch therapy as a new β-blocker medication. In addition, cardiovascular complications (all-cause death, cardiac death, heart failure, ventricular tachycardia, and ventricular fibrillation) during the perioperative period were evaluated.

Results

There was no significant change in the patients’ heart rate, blood pressure, ejection fraction, and pressure gradient in the left ventricle after switching from oral bisoprolol to the transdermal patch therapy. On the other hand, patients who started using the bisoprolol transdermal patch as a new ß-blocker medication tended to have a decreased heart rate and pressure gradient thereafter, but there was no significant difference in blood pressure or ejection fraction. No cardiovascular complications occurred during the perioperative period.

Conclusions

We described the utilization of the bisoprolol transdermal patch during perioperative care for non-cardiac surgery in patients with HOCM. We determined that the hemodynamic features of these patients did not change significantly after switching to patch therapy. Further, initiation of the bisoprolol transdermal patch as a new ß-blocker medication sufficiently tended to decrease the pressure gradient. This unique approach can be an alternate treatment option for HOCM.

Trial registration

The registry was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000036703). The date of registration was 10/5/2019 and it was “Retrospectively registered”.
Appendix
Available only for authorised users
Literature
1.
go back to reference Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33:1590–5.CrossRef Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical profile of hypertrophic cardiomyopathy identified de novo in rural communities. J Am Coll Cardiol. 1999;33:1590–5.CrossRef
2.
go back to reference Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Thorac Cardiovasc Surg. 2011;142:e153–203.CrossRef Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Thorac Cardiovasc Surg. 2011;142:e153–203.CrossRef
3.
go back to reference JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy (JCS 2012) - digest version. Circ J. 2016;80:753–74.CrossRef JCS Joint Working Group. Guidelines for diagnosis and treatment of patients with hypertrophic cardiomyopathy (JCS 2012) - digest version. Circ J. 2016;80:753–74.CrossRef
4.
go back to reference Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–9.CrossRef Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation. 2006;114:2232–9.CrossRef
5.
go back to reference Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRef Authors/Task Force members, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–79.CrossRef
6.
go back to reference Hreybe H, Zahid M, Sonel A, Good CB, Shaver J, Saba S. Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2006;29:65–8.CrossRef Hreybe H, Zahid M, Sonel A, Good CB, Shaver J, Saba S. Noncardiac surgery and the risk of death and other cardiovascular events in patients with hypertrophic cardiomyopathy. Clin Cardiol. 2006;29:65–8.CrossRef
7.
go back to reference Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21:1672–9.CrossRef Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. J Am Coll Cardiol. 1993;21:1672–9.CrossRef
8.
go back to reference Momomura SI, Saito Y, Yasumura Y, Yamamoto K, Sakata Y, Daimon M, et al. Efficacy and safety of switching from oral bisoprolol to transdermal patch in Japanese patients with chronic heart failure. Circ J. 2017;82:141–7.CrossRef Momomura SI, Saito Y, Yasumura Y, Yamamoto K, Sakata Y, Daimon M, et al. Efficacy and safety of switching from oral bisoprolol to transdermal patch in Japanese patients with chronic heart failure. Circ J. 2017;82:141–7.CrossRef
9.
go back to reference Matsuoka H, Kuwajima I, Shimada K, Mitamura H, Saruta T. Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study. J Clin Hypertens (Greenwich). 2013;15:806–14.CrossRef Matsuoka H, Kuwajima I, Shimada K, Mitamura H, Saruta T. Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study. J Clin Hypertens (Greenwich). 2013;15:806–14.CrossRef
10.
go back to reference Park TH, Tayan N, Takeda K, Jeon HK, Quinones MA, Zoghbi WA. Supine bicycle echocardiography improved diagnostic accuracy and physiologic assessment of coronary artery disease with the incorporation of intermediate stages of exercise. J Am Coll Cardiol. 2007;50:1857–63.CrossRef Park TH, Tayan N, Takeda K, Jeon HK, Quinones MA, Zoghbi WA. Supine bicycle echocardiography improved diagnostic accuracy and physiologic assessment of coronary artery disease with the incorporation of intermediate stages of exercise. J Am Coll Cardiol. 2007;50:1857–63.CrossRef
11.
go back to reference Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J Am Coll Cardiol. 2015;66:403–69.CrossRef Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association task force on clinical data standards (writing committee to develop cardiovascular endpoints data standards). J Am Coll Cardiol. 2015;66:403–69.CrossRef
12.
go back to reference Glance LG, Lustik SJ, Hannan EL, Osler TM, Mukamel DB, Qian F, et al. The surgical mortality probability model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg. 2012;255:696–702.CrossRef Glance LG, Lustik SJ, Hannan EL, Osler TM, Mukamel DB, Qian F, et al. The surgical mortality probability model: derivation and validation of a simple risk prediction rule for noncardiac surgery. Ann Surg. 2012;255:696–702.CrossRef
13.
go back to reference Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383–431.13.CrossRef Kristensen SD, Knuuti J, Saraste A, Anker S, Botker HE, Hert SD, et al. 2014 ESC/ESA guidelines on non-cardiac surgery: cardiovascular assessment and management: the joint task force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA). Eur Heart J. 2014;35:2383–431.13.CrossRef
14.
go back to reference London MJ. Perioperative beta-blockade, discontinuation, and complications: do you really know it when you see it? Anesthesiology. 2009;111:690–4.CrossRef London MJ. Perioperative beta-blockade, discontinuation, and complications: do you really know it when you see it? Anesthesiology. 2009;111:690–4.CrossRef
15.
go back to reference Ross PJ, Lewis MJ, Sheridan DJ, Henderson AH. Adrenergic hypersensitivity after beta-blocker withdrawal. Br Heart J. 1981;45:637–42.CrossRef Ross PJ, Lewis MJ, Sheridan DJ, Henderson AH. Adrenergic hypersensitivity after beta-blocker withdrawal. Br Heart J. 1981;45:637–42.CrossRef
16.
go back to reference Gilligan DM, Chan WL, Stewart R, Oakley CM. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol. 1991;68:766–72.CrossRef Gilligan DM, Chan WL, Stewart R, Oakley CM. Adrenergic hypersensitivity after beta-blocker withdrawal in hypertrophic cardiomyopathy. Am J Cardiol. 1991;68:766–72.CrossRef
17.
go back to reference Sairaku A, Nakano Y, Shiode N, Suenari K, Oda N, Ono K, et al. Head-to-head comparison of the heart rate variability between the bisoprolol transdermal patch and bisoprolol fumarate tablet. Cardiovasc Ther. 2018;36:e12325.CrossRef Sairaku A, Nakano Y, Shiode N, Suenari K, Oda N, Ono K, et al. Head-to-head comparison of the heart rate variability between the bisoprolol transdermal patch and bisoprolol fumarate tablet. Cardiovasc Ther. 2018;36:e12325.CrossRef
18.
go back to reference Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–8.CrossRef Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–8.CrossRef
19.
go back to reference MacIntyre C, Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2016;133:1901–5.CrossRef MacIntyre C, Lakdawala NK. Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation. 2016;133:1901–5.CrossRef
20.
go back to reference Schwartz M, Michelson EL, Sawin HS, MacVaugh H 3rd. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. Chest. 1988;93:705–11.CrossRef Schwartz M, Michelson EL, Sawin HS, MacVaugh H 3rd. Esmolol: safety and efficacy in postoperative cardiothoracic patients with supraventricular tachyarrhythmias. Chest. 1988;93:705–11.CrossRef
21.
go back to reference Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-land study). Circ J. 2013;77:908–16.CrossRef Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, et al. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting beta1-selective blocker landiolol with digoxin (J-land study). Circ J. 2013;77:908–16.CrossRef
22.
go back to reference Nakamura K, Inokuchi R, Hiruma T, Tokunaga K, Doi K, Nakajima S. Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. J Anesth. 2016;30:891–4.CrossRef Nakamura K, Inokuchi R, Hiruma T, Tokunaga K, Doi K, Nakajima S. Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. J Anesth. 2016;30:891–4.CrossRef
23.
go back to reference Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67:1399–409.CrossRef Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2016;67:1399–409.CrossRef
Metadata
Title
Bisoprolol transdermal patch for perioperative care of non-cardiac surgery in patients with hypertrophic obstructive cardiomyopathy
Authors
Yoichi Imori
Hitoshi Takano
Hiroshi Mase
Junya Matsuda
Hideto Sangen
Yuki Izumi
Yukichi Tokita
Takeshi Yamamoto
Wataru Shimizu
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2019
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-019-01274-6

Other articles of this Issue 1/2019

BMC Cardiovascular Disorders 1/2019 Go to the issue